CBS 2019
CBSMD教育中心
中 文

Transcatheter Aortic Valve Replacement

Abstract

Recommended Article

Leaflet immobility and thrombosis in transcatheter aortic valve replacement Association Between Diastolic Dysfunction and Health Status Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement The Utility of Rapid Atrial Pacing Immediately Post-TAVR to Predict the Need for Pacemaker Implantation Left Ventricular Hypertrophy and Clinical Outcomes Over 5 Years After TAVR: An Analysis of the PARTNER Trials and Registries 5-Year Outcomes After TAVR With Balloon-Expandable Versus Self-Expanding Valves: Results From the CHOICE Randomized Clinical Trial Frailty in Older Adults Undergoing Aortic Valve Replacement: The FRAILTY-AVR Study von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week Infective Endocarditis After Transcatheter Aortic Valve Replacement

Original ResearchSeptember 2019

JOURNAL:J Am Coll Cardiol. Article Link

Gender Differences in Transfemoral Transcatheter Aortic Valve Replacement

W Vlastra, J Chandrasekhar, BGD Blanco et al. Keywords: transfemoral aortic valve implantation; gender differences; predictors of 30-day mortality; outcome differences over time

ABSTRACT


BACKGROUND - Transfemoral aortic valve replacement (TAVR) is a guideline-recommended treatment option for patients with severe aortic valve stenosis. Females and males present with different baseline characteristics, which may influence procedural outcomes.


OBJECTIVES - To evaluate differences between females and males undergoing transfemoral TAVR across the globe during the last decade.


METHODS - The CENTER collaboration was a global patient level dataset of patients undergoing transfemoral TAVR (N= 12,381) from 2007-2018. In this retrospective analysis we examined differences in baseline patient characteristics, 30-day stroke and mortality and in-hospital outcomes between female and male patients. We also assessed for temporal changes in outcomes and predictors for mortality per gender.


RESULTS - We included 58% (n=7,120) female and 42% (n=5,261) male patients. Females had higher prevalence of hypertension and glomerular filtration rate <30ml/min/m2, but lower prevalence of all other traditional cardiovascular comorbidities. Both genders had similar rates of 30-day stroke (2.3% vs 2.5%, p=0.53) and mortality (5.9% vs. 5.5%, p=0.17). In contrast, females had a 50% higher risk of life-threatening or major bleeding (6.7% vs 4.4%, p<0.01). Over the study period mortality rates decreased to a greater extent in males than in females (60% vs 50% reduction, both p<0.001), with no reductions in stroke rates over time.


CONCLUSIONS - In this global collaboration females and males had similar rates of 30-day mortality and stroke. However, females had higher rates of procedural life-threatening or major bleeding after TAVR. Between 2007 and 2018 mortality rates decreased to a greater extent in males than in females.